TREM2 and Alzheimer disease: The amount of soluble (s) TREM2 is increased in the CSF of AD patients and seems to sustain microglial viability, and to trigger inflammatory responses by the Akt–GSK3β–β-catenin and NF-κB pathway in vitro [421,422].